首页> 美国卫生研究院文献>other >Paeoniflorin Inhibits Mesangial Cell Proliferation and Inflammatory Response in Rats With Mesangial Proliferative Glomerulonephritis Through PI3K/AKT/GSK-3β Pathway
【2h】

Paeoniflorin Inhibits Mesangial Cell Proliferation and Inflammatory Response in Rats With Mesangial Proliferative Glomerulonephritis Through PI3K/AKT/GSK-3β Pathway

机译:eon药苷通过PI3K / AKT /GSK-3β途径抑制系膜增生性肾小球肾炎大鼠系膜细胞增殖和炎症反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mesangial proliferative glomerulonephritis (MPGN) is the most common type of chronic kidney disease in China, characterized by mesangial cell proliferation and inflammatory response. Paeoniflorin, an effective composition extracted from Radix Paeoniae Alba, has been used for various kinds of kidney diseases. However, there are no studies reporting the effects of paeoniflorin on MPGN. The present study aims to investigate whether paeoniflorin plays a role in MPGN and confirm the underlying molecular mechanisms. Our results manifested that paeoniflorin strongly restrained 24 h urinary protein and promoted renal function and dyslipidemia in a MPGN rat model. Moreover, paeoniflorin attenuated mesangial cell proliferation and inflammation both in MPGN rats and human mesangial cells (HMCs) treated with lipopolysaccharide (LPS). In detail, paeoniflorin decreased the number of mesangial cells and expressions of proliferation marker Ki67 in MPGN rats. Paeoniflorin also inhibited HMC proliferation and blocked cell cycle progression. In addition, the contents of inflammatory factors and the expressions of macrophage marker iNOS were decreased after paeoniflorin treatment. Furthermore, we found that the protective effect of paeoniflorin was accompanied by a strong inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT/glycogen synthase kinase (GSK)-3β pathway. Paeoniflorin enhanced the inhibitory effect of PI3K inhibitor and suppressed the activated effect of PI3K agonist insulin-like growth factor 1 (IGF-1) on PI3K/AKT/GSK-3β pathway. In conclusion, these results demonstrated that paeoniflorin ameliorates MPGN by inhibiting mesangial cell proliferation and inflammatory response through the PI3K/AKT/GSK-3β pathway.
机译:肾小球膜增生性肾小球肾炎(MPGN)是中国最常见的慢性肾脏疾病,其特征是肾小球膜细胞增殖和炎症反应。 eon药苷是从Pa药丹参中提取的有效成分,已用于多种肾脏疾病。但是,尚无研究报告eon药苷对MPGN的影响。本研究旨在调查pa药苷是否在MPGN中起作用并确认潜在的分子机制。我们的结果表明,pa药苷在MPGN大鼠模型中强烈抑制24 h尿蛋白并促进肾功能和血脂异常。此外,pa药花青素可减轻MPGN大鼠和经脂多糖(LPS)处理的人系膜细胞(HMC)的系膜细胞增殖和炎症。详细地讲,pa药苷减少了MPGN大鼠系膜细胞的数量和增殖标记Ki67的表达。 eon药苷还抑制HMC增殖并阻止细胞周期进程。此外,pa药苷处理后炎症因子的含量和巨噬细胞标志物iNOS的表达降低。此外,我们发现pa药苷的保护作用伴随着对磷脂酰肌醇3-激酶(PI3K)/ AKT /糖原合酶激酶(GSK)-3β途径的强烈抑制。 eon药苷增强PI3K抑制剂的抑制作用,并抑制PI3K激动剂胰岛素样生长因子1(IGF-1)对PI3K / AKT /GSK-3β途径的激活作用。总之,这些结果表明pa药苷通过抑制肾小球膜细胞增殖和通过PI3K / AKT /GSK-3β途径的炎症反应来改善MPGN。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号